Hetero recalls a batch of its remdesivir brand Covifor after side effects

Some patients in Raigad district of Maharashtra developed side effects like fever and chills

Topics

Hetero Group | Remdesivir | Pharma


Sohini Das  | 
Mumbai 

Hetero, remdesivir, Covifor, coronavirus, covid, vaccine, drugs, pharma

Hyderabad-based pharma company Hetero has recalled a batch of its remdesivir brand Covifor after some patients in Raigad district of Maharashtra developed side effects like fever and chills after being administered the drug.

In a letter dated April 29, Hetero Healthcare Director N Bose asked all hospitals, institutions, and stockists to withhold and not use Covifor batch no HCL21013 supplied from the company’s C&F agents due to technical reasons until further instructions. Maharashtra’s Foods & Drugs Administration Minister Rajendra Shingane had said around 90 patients in Raigad district of Maharashtra, who were administered remdesivir doses of a particular brand, developed severe side effects.

Following this, the state government had imposed a temporary suspension on its use. Patients developed chills and fever which were addressed by the district medical authorities. The patients are stable now, Shingane had said. He could not be reached for a comment. Hetero said the company decided to recall the batch as a precautionary measure.

The batch was distributed in Maharashtra and no other incident has come to the company’s notice, it said.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 04 2021. 23:39 IST